V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Ultragenyx Pharmaceutical Executive Compensation (FY25)

RARE · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Emil Kakkis
Latest say-on-pay support
=
May 14, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Ultragenyx Pharmaceutical brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 22, 2026Latest filing (8-K): May 18, 2026
14 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Ultragenyx Pharmaceutical brief$1,500Get the executive brief
Velarion Member, one year
335 figures on this page: 325 cited to the filing that reported them, 10 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Emil Kakkis: $13,717,687 → $11,405,535 (16.9% lower)
CEO pay ratio: 42:1 → 38:1 (9.5% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Ultragenyx Pharmaceutical's chief executive and what were they paid?
Emil Kakkis, President and Chief Executive Officer, received $11,405,535 in total compensation for fiscal 2025. Compared with the $13,717,687 reported for fiscal 2024, Kakkis' total was 16.9% lower.
What was Ultragenyx Pharmaceutical's say-on-pay result?
The say-on-pay proposal drew 96.5% of votes cast for or against in favor at the meeting held May 14, 2026 for fiscal 2025.
Which companies are in Ultragenyx Pharmaceutical's peer group?
The disclosed peer group includes ACADIA Pharmaceuticals Inc., Alkermes plc, Amicus Therapeutics, Apellis Pharmaceuticals, Inc. and Axsome Therapeutics, Inc., among others.
What is Ultragenyx Pharmaceutical's chief executive pay ratio?
The company reported a chief executive pay ratio of 38:1 for fiscal 2025, against median employee compensation of $302,376.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Emil Kakkis
President and Chief Executive Officer
◇—◇◇◇—◇◇
Mardi Dier
Former Chief Financial Officer and Executive Vice President
Departed during or after this year
◇—◇◇——◇◇
Camille Bedrosian
Chief Medical Officer
◇—◇◇◇—◇◇
Erik Harris
Chief Commercial Officer and Executive Vice President
◇—◇◇◇—◇◇
John Pinion
Chief Quality Officer and Executive Vice President, Translational Sciences
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Emil Kakkis
President and Chief Executive Officer
◇—◇◇◇—◇◇
Howard Horn
Chief Financial Officer
◇◇◇◇———◇
Karah Parschauer
Chief Legal Officer and Secretary
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Emil Kakkis
President and Chief Executive Officer
◇—◇◇◇—◇◇
Eric Crombez
Chief Medical Officer and Executive Vice President
◇—◇◇◇—◇◇
Howard Horn
Chief Financial Officer
◇—◇◇◇—◇◇
Erik Harris
Chief Commercial Officer and Executive Vice President
◇—◇◇◇—◇◇
John Pinion
Chief Quality Officer and Executive Vice President, Translational Sciences
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Emil Kakkis
President and Chief Executive Officer
◇—◇◇◇—◇◇
Erik Harris
Chief Commercial Officer and Executive Vice President
◇—◇◇◇—◇◇
Eric Crombez
Chief Medical Officer and Executive Vice President
◇—◇◇◇—◇◇
Howard Horn
Chief Financial Officer, Corporate Strategy and Executive Vice President
◇—◇◇◇—◇◇
Karah Parschauer
Chief Legal Officer & Corporate Affairs, Executive Vice President
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Emil D. KakkisOPTION◇——◇—◇◇
Emil D. KakkisPSU◇◇◇—◇—◇
Emil D. KakkisRSU◇——◇——◇
Eric CrombezRSU◇——◇——◇
Eric CrombezPSU◇◇◇—◇—◇
Eric CrombezOPTION◇——◇—◇◇
Erik HarrisRSU◇——◇——◇
Erik HarrisPSU◇◇◇—◇—◇
Erik HarrisOPTION◇——◇—◇◇
Howard HornRSU◇——◇——◇
Howard HornPSU◇◇◇—◇—◇
Howard HornOPTION◇——◇—◇◇
Karah ParschauerPSU◇◇◇—◇—◇
Karah ParschauerRSU◇——◇——◇
Karah ParschauerOPTION◇——◇—◇◇
Fiscal 2022 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Erik HarrisPSU◇◇——
Option◇—◇3/1/2035
RSU◇◇——
Option◇—◇3/1/2032
RSU◇◇——
PSU◇◇——
Option◇—◇3/1/2034
RSU◇◇——
Option◇—◇3/1/2033
RSU◇◇——
Howard HornPSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇10/9/2033
RSU◇◇——
Option◇—◇10/21/2034
Option◇—◇3/1/2035
Option◇—◇3/1/2034
PSU◇◇——
Karah ParschauerPSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/1/2034
RSU◇◇——
RSU◇◇——
Option◇—◇3/1/2035
Option◇—◇10/21/2034
Option◇—◇3/1/2033
Option◇—◇3/1/2032
PSU◇◇——
Eric CrombezRSU◇◇——
RSU◇◇——
Option◇—◇3/1/2035
Option◇—◇5/1/2033
RSU◇◇——
Option◇—◇3/1/2034
RSU◇◇——
PSU◇◇——
Option◇—◇3/1/2033
Option◇—◇3/1/2032
PSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Emil Kakkis
President and Chief Executive Officer · Terms as described in the company’s compensation discussion
Severance multiple◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Daniel G. Welch
Board chair
◇◇◇———◇
Michael Narachi
◇◇◇———◇
Matthew K. Fust
◇◇◇———◇
Shehnaaz Suliman
◇◇◇———◇
Corsee D. Sanders
◇◇◇———◇
Deborah Dunsire
◇◇◇———◇
Amrit Ray
◇◇◇———◇
Emil D. Kakkis served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Stock ownership guideline: We require our executive officers and directors to hold shares of our common stock in order to align their long-term interests with those of our stockholders; see “—Minimum Stock Ownership Requirements”.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • ACADIA Pharmaceuticals Inc. ACAD
  • Alkermes plc ALKS
  • Amicus Therapeutics FOLD
  • Apellis Pharmaceuticals, Inc. APLS
  • Axsome Therapeutics, Inc. AXSM
  • Blueprint Medicines Corporation BPMC
  • BridgeBio Pharma, Inc. BBIO
  • Corcept Therapeutics Inc. CORT
  • Denali Therapeutics Inc. DNLI
  • Exelixis Inc. EXEL
  • Halozyme Therapeutics HALO
  • Insmed Incorporated INSM
  • Intra-Cellular Therapies Inc. ITCI
  • Ionis Pharmaceuticals, Inc. IONS
  • Jazz Pharmaceuticals plc JAZZ
  • Neurocrine Biosciences, Inc. NBIX
  • PTC Therapeutics, Inc. PTCT
  • Sarepta Therapeutics, Inc. SRPT
  • Vericel Corporation VCEL

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 14, 2026=◇◇◇
2024May 15, 2025=◇◇◇
2023June 18, 2024=◇◇◇
2022June 7, 2023=◇◇◇
2020June 24, 2021=◇◇◇
2019June 26, 2020=◇◇◇
2018June 11, 2019=◇◇◇
2017June 19, 2018=◇◇◇
2016June 22, 2017=◇◇◇
2015June 9, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Emil Kakkis (President and Chief Executive Officer), FY2025 total compensation $11,405,535 (base salary $861,100) [exec_comp, SEC accession 0001308179-26-000174, filed 2026-03-27]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Ultragenyx Pharmaceutical files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Ultragenyx Pharmaceutical disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Ultragenyx Pharmaceutical sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Ultragenyx Pharmaceutical's disclosed peer group is defensible, who names Ultragenyx Pharmaceutical back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
335 figures on this page: 325 cited to the filing that reported them, 10 calculated from figures it prints.
325 cited to the filing
10 calculated from the filing

Documents cited

  1. 0001193125-26-228639
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001308179-26-000174
    CEO Pay Ratio · Director Compensation · Grants of Plan-Based Awards · Outstanding Equity Awards at December 31, 2025 · and 2 more sections
  3. 0000950170-25-074529
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001308179-25-000296
    Summary Compensation Table
  5. 0000950170-24-076222
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001308179-24-000609
    Summary Compensation Table
  7. 0000950170-23-027644
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001308179-23-000757
    Summary Compensation Table
  9. 0000950170-21-000388
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001564590-20-031076
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001564590-19-022660
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001564590-18-015905
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0001564590-17-012902
    Item 5.07 Submission of Matters to a Vote of Security Holders
  14. 0001193125-16-622434
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Ultragenyx Pharmaceutical executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/RARE (accessed 2026).
Short form: data: Velarion

The Ultragenyx Pharmaceutical brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
14 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Ultragenyx Pharmaceutical and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Ultragenyx Pharmaceutical discloses

The companies named in RARE's own disclosed peer group.

ACADIA Pharmaceuticals Inc.Alkermes plcAmicus TherapeuticsApellis Pharmaceuticals, Inc.Axsome Therapeutics, Inc.Blueprint Medicines CorporationBridgeBio Pharma, Inc.Corcept Therapeutics Inc.Denali Therapeutics Inc.Exelixis Inc.Halozyme TherapeuticsInsmed IncorporatedIntra-Cellular Therapies Inc.Ionis Pharmaceuticals, Inc.Jazz Pharmaceuticals plcNeurocrine Biosciences, Inc.PTC Therapeutics, Inc.Sarepta Therapeutics, Inc.Vericel Corporation

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy